In Re. Xxxxx Xxx Xxxxxxx, Xx. 00-00000 (Xxxxxx Xxxxxx Bankruptcy Court, Northern District of Ohio). Creditor challenging legacy structured settlement order in annuitant’s Chapter 7 Bankruptcy proceeding.
In Re. Yasmin and YAZ (Drospirenone) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2100 (the “MDL”), a federal multi-district litigation venued in the United States District Court for the Southern District of Illinois (the “MDL Court”); (2) any other federal court proceedings pertaining to actions, disputes, and claims asserted against Defendants regarding the use of drospirenone- containing oral contraceptives manufactured by Bayer or manufactured or marketed by BarrTeva (collectively, “DCOCs”), either pending in that court or removed therefrom and awaiting transfer to the MDL (collectively, the “Other Federal Court Proceedings”), and (3) In re Yaz, Yasmin and Ocella Contraceptive Cases, Case No. JCCP 4608 (Superior Court of the State of California, County of Los Angeles) (the “California Coordinated Proceedings”), In RE: Yaz/Yasmin/Ocella Litigation, BER-L-3572-10 (Superior Court, Law Division, Bergen County) (the “New Jersey Coordinated Proceedings”), and In re: Yaz/Yasmin/Ocella/Gianvi Products Liability Litigation, September Term, 2009. No 1307 (Court of Common Pleas of Philadelphia County, Trial Division-Civil) (the “Philadelphia Court of Common Pleas Coordinated Proceeding”) pending in their respective courts (collectively, the “State Coordinating Courts”). The Gallbladder Resolution Program established pursuant to this Settlement Agreement also is open to Claimants in any and all other state court proceedings pertaining to actions, disputes, and claims asserted against Defendants regarding the use of DCOCs (together with the cases pending in the State Coordinating Courts, the “State Court Proceedings”).
In Re. NuvaRing Litigation, BER-L-3081-09 (the “New Jersey Coordinated Proceedings”), venued in the New Jersey Superior Court, Law Division, Bergen County (the “New Jersey Coordinated Court”); and (4) any and all other state court proceedings pertaining to actions, disputes, and claims asserted against Defendants regarding the use of NuvaRing (the “Other State Court Proceedings”).
In Re. Actos (Pioglitazone) Products Liability Litigation, MDL No. 2299 (the “MDL”), a federal multi- district litigation venued in the United States District Court for the Western District of Louisiana (the “MDL Court”); (2) any other federal court proceedings, either pending in that court or awaiting transfer to the MDL (collectively, the “Other Federal Court Proceedings”); (3) In re Actos Related Cases, No. 2011 L 010011 (the “Illinois Coordinated Proceedings”), venued in the Circuit Court of Xxxx County, Illinois, County Department, Law Division (the “Illinois Coordinated Court”); (4) In Re Actos Product Liability Cases Coordinated Proceeding, JCCP No. 4696 (the “California Coordinated Proceedings”), venued in the California Superior Court, Los Angeles County, California (the “California Coordinated Court”); and (5) any and all other state court proceedings (the “Other State Court Proceedings”).
In Re. Xxxxxxx Xxxxxx, No. 1:15-bk-02164 (Bankr. M.D. Tenn.)
In Re. Rust-Oleum Restore Marketing, Sales Practices and Products Liability Litig., No. 1:15-cv-01364 (N.D. Ill.); In re: Sears, Xxxxxxx and Co. Front-Loader Washer Products Liability Litig., No. 1:06-cv-07023 (N.D. Ill.); Xxxxx x. Xxxxxx Nutrition International, Inc., No. 3:11-CV-01056 (S.D. Cal.); Xxxx v.
In Re. Power Purchase Agreement between Duke Energy Progress, LLC and Olanta Solar, LLC ) ) ) ) ) ) PROPOSED ORDER RULING ON REQUEST FOR CONFIDENTIALITY This matter comes before the Public Service Commission of South Carolina (“Commission”) upon the filing of an amendment to a Power Purchase Agreement (“PPA”) between Duke Energy Progress, LLC (“DEP” or the “Company”) and Olanta Solar, LLC (“Olanta Solar”) with the Commission (“October 5 Filing”). The amendment revised the PPA previously accepted for filing by the Commission in Order No. 2016-146 (“Amendment”). In the October 5 Filing, DEP submitted a request for confidential treatment due to the commercially sensitive and proprietary nature of certain portions of the Amendment. DEP included with the October 5 Filing a redacted version of the Amendment illustrating the portions for which confidentiality was sought. On October 24, 2017, the Office of Regulatory Staff (“ORS”) filed a letter objecting to DEP’s confidentiality request, noting that certain headers, column labels, and definitions were redacted, and requested that the Commission deny the Company’s request unless and until the Company demonstrated why the redacted provisions are confidential. On December 1, 2017, DEP filed a revised Amendment with fewer redactions along with a memorandum supporting its request for confidential treatment. On December 5, 2017, ORS filed a letter maintaining its objection to DEP’s confidentiality ELECTRONICALLY FILED - 2018 February 26 3:26 PM - SCPSC - Docket # 2016-42-E - Page 2 of 8 request. On December 8, 2017, the standing hearing officer issued a directive indicating that the Commission would rule on DEP’s request for confidentiality in its December 20, 2017 business meeting and instructing the parties to file any further briefs by December 13, 2017. DEP filed a brief on December 13, 2017, and, on December 20, 2017, the Commission issued a directive requiring that the Amendment remain sealed and instructed Commission staff to schedule an oral argument as to the redacted documents. An oral argument was held on February 6, 2018. For the reasons stated herein, we accept the Amendment to the PPA for filing and grant DEP’s request to treat the Amendment as confidential. FINDINGS AND CONCLUSIONS
In Re. Human Tissue Litigation Donor Families vs. Biomedical Tissue Services, et al, as more particularly described on filings made by the Borrower with the Securities and Exchange Commission. SCHEDULE 3.12 SUBSIDIARIES Subsidiaries of RTI Bioligics, Inc. Biologic Recovery Group, Inc. RTI Services, Inc. Regeneration Technologies, Inc. – Cardiovascular Tutogen Medical, Inc. RTI Donor Service, Inc. (controlled) Subsidiaries of Tutogen Medical, Inc. Tutogen Medical (United States), Inc. Tutogen Medical, GmbH (Germany) Tutogen Medical, SARL (France) [Subsidiary of Tutogen Medical GmbH] Subsidiaries of Tutogen Medical (United States), Inc. None. SCHEDULE 3.13 PLACE OF BUSINESS Previous Locations of Chief Executive Office of Tutogen Medical, Inc. and Tutogen Medical (United States), Inc.: From 1/1/2006-2/27/2008: Onx Xxxxxxxx Xxxxxxxxx Xxxxxxx, Xxxxxxx 00000 Prior to 1/1/2006: 1100 XxXxxxx Xxxxxx, West Paterson New Jersey 07424 SCHEDULE 3.14 NAME CHANGE On 2/27/08, as a result of the merger with Tutogen Medical, Inc., Regeneration Technologies, Inc. became RTI Biologics, Inc. SCHEDULE 4.1(F) HAZARDOUS SUBSTANCES ON REAL ESTATE Diesel Fuel Acetone Human tissues SCHEDULE 4.2(f) LOANS TO OTHERS None. SCHEDULE 4.2(g) INDEBTEDNESS/GUARANTEES Lender Debt Instrument 12-31-08 Amount (1) Maturity Date HypoVereinsbank (2) Term Loan $ 374k 6-30-2011 HypoVereinsbank Term Loan $ 1,145k 3-30-2012 HypoVereinsbank Term Loan $ 1,240k 12-30-2016 HypoVereinsbank (3) Interim Constr $ 1,224k TBD HypoVereinsbank Term Loan $ 275k 9-30-2012 HypoVereinsbank LOC $ 1,442k Revolving
In Re. DEPARTMENT OF JOB AND FAMILY SERVICES…PURCHASE OF SERVICE AGREEMENT WITH A FAMILY FOR EVERY CHILD FOR THE PROVISION OF ADOPTION SERVICES FOR SAME…18-0503- 005…
In Re. BOARD OF COUNTY COMMISSIONERS…ESTABLISHMENT OF THE REIMBURSEMENT RATE FOR EACH MILE NECESSARILY TRAVELED BY A WITNESS IN A CIVIL AND/OR CRIMINAL CASE IN THE CLERMONT COUNTY COMMON PLEAS COURT, ANY DIVISION OF THE CLERMONT COUNTY COMMON PLEAS COURT, AND/OR THE CLERMONT COUNTY MUNICIPAL COURT…00-0000-000 Recommendation to establish the reimbursement rate of fifty and one-half cents ($0.505) for each mile necessarily traveled by a witness in a civil and/or criminal case in the Clermont County Common Pleas Court, any division of the Clermont County Common Pleas Court, and/or the Clermont County Municipal Court, pursuant to and in compliance with Sections 2335.06 and 2335.08 of the Ohio Revised Code entitled Witness Fees in Civil Cases and Witness Fees in Criminal Cases, respectively, effective 06/01/2018.
